Imara completed dosing patients in the IMR-687 Phase 2a clinical trial in patients with SCD during the third quarter of 2020 and plans to report top-line data late in the fourth quarter of 2020 ...

BOSTON, June 11, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients ...

Imara reports additional pre-clinical and Phase 1 data for lead compound, IMR-687, at the 6th Annual Sickle Cell Therapeutics Conference in New York.

Oral presentation provides first look at new program, IMR-261, a novel, oral, clinic-ready nuclear factor erythroid 2-related factor 2 (Nrf2) activator SCD Townes mouse model demonstrates IMR-261 ...

Final data from 93-patient Phase 2a clinical trial show lower annualized rate of vaso-occlusive crises (VOCs) and longer time to first VOC on IMR-687 Interim open-label extension clinical trial ...

Imara Presented Positive, Interim Phase 2a Data on IMR-687 for the Treatment of Sickle Cell Disease at the 24th Congress of the European Hematology Association ...

The 110 propellants listed in the Hornady Handbook of Cartridge Reloading Fifth Edition appear in order of burn rate, from fastest to slowest. IMR 7828 is 100th.

Final data from 93-patient Phase 2a clinical trial show lower annualized rate of vaso-occlusive crises (VOCs) and longer time to first VOC on IMR-687 Interim open-label extension clinical trial data ...